Confocal microscopy manufacturer Optiscan Imaging is looking to expand into the veterinary market with its microscopy imaging system with an initial focus on cancer detection in companion animals. The company has signed MOU with the University of Minnesota College of Veterinary Medicine to enable the development of clinical data for Optiscan’s digital confocal laser endomicroscopic…
Confocal microscopy manufacturer Optiscan Imaging has completed the beta phase development of its cloud-connected telepathology platform developed in partnership with Prolucid Technologies. The development is a significant advancement in digital pathology, according to the company, enabling real-time, remote collaboration on patient imaging sessions. The platform utilises Optiscan’s confocal imaging technology to generate digital pathology data,…
Microscopic imaging technology company Optiscan Imaging has revealed an innovative new medical imaging device, InVue, which is designed to enable precision surgery through real-time digital pathology. Manufactured in Melbourne in partnership with industrial design firm Design + Industry, InVue is a significant milestone for the company, traditionally known for its confocal microscope devices. Optiscan CEO…
Optiscan Imaging has entered into a collaboration through a know-how agreement with Mayo Clinic in the US to develop a digital confocal laser endomicroscopic imaging system for use in robotic surgery. The collaboration combines Optiscan’s engineering expertise in digital endomicroscopic hardware and software development with Mayo Clinic’s know-how in robotic surgery and quality patient care,…
Medical imaging technology manufacturer Optiscan Imaging has completed a key milestone in its development of telepathology utilising its imaging systems that visualise biological structures in their natural environment. The company has been working with Canada’s Prolucid Technologies developing a telepathology platform that enables pathologists to undertake virtual biopsy assessments. The project has now passed the…
